PC model disentangles puzzle behind serious aggravation in individuals with COVID-19 Kumar Jeetendra | September 29, 2020 A study from the University of Pittsburgh School of Medicine and Cedars-Sinai addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation? The research shows how the molecular arrangement and arrangement of the SARS-CoV-2 spike protein–part of the virus that causes COVID-19–could be behind the inflammatory syndrome cropping up …
Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay Kumar Jeetendra | September 30, 2020 Mechelen, Belgium, 30 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular …
Russia finishes clinical preliminaries of second potential COVID-19 immunization Kumar Jeetendra | September 30, 2020 Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute, the RIA news agency mentioned Russian customer safety watchdog Rospotrebnadzor as saying on Wednesday The institute completed early-stage human trials, known as Phase II, earlier this month.
GlaxoSmithKline CEO hopeful COVID-19 immunization generally accessible in 2021 Kumar Jeetendra | September 30, 2020 The chief executive of GlaxoSmithKline, the world’s largest maker of vaccines, said she was convinced that the industry will have the ability to make an immunisation against COVID-19 widely available next year. “I share the optimism that we’ll have solutions next year. The challenge here is getting into the scale that’s required,” GSK CEO Emma …
Moderna COVID-19 antibody seems safe, gives indications of working in more seasoned grown-ups: Study Kumar Jeetendra | September 30, 2020 Results from an early safety study of Moderna Inc’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those found in younger adults, with side effects about on par with high-dose flu shots, researchers said on Tuesday. The study, published in the New England Journal of Medicine, offers …
Researchers distinguish interesting examples in COVID-19 transmission in India Kumar Jeetendra | October 1, 2020 Researchers, including those from the Government of Tamil Nadu, and Andhra Pradesh, have conducted one of the largest analysis of COVID-19 epidemiology to date, and have discovered that both cases and deaths due to the disease are more heavily concentrated in the 40-69 year age group in India than is seen in high-income nations, among …
An interview with Mr Pradip Popat Chairman Apex Chromatography Pvt Ltd Kumar Jeetendra | October 1, 2020 We have established many brands in India with an ethos of quality over pricing, showing that an investment in better quality materials has much better long-term benefits an interview with Mr Pradip Popat, Chairman Apex Chromatography Pvt Ltd. Mr Pradip Popat founded Apex Chromatography 40 years ago with family and presently serving as chairman of …
An Interview with Mr. Surendra Kumar Agarwal, Chairman and MD Sisco Research Laboratories Pvt.Ltd Kumar Jeetendra | October 1, 2020 Sisco Research Laboratories Pvt. Ltd. (SRL) is one such organization that stands amongst the oldest and most respected manufacturers of specialty fine chemicals, microbiological, nanotechnology and biotechnology reagents. Mr S. K. Agarwal laid the foundation of SRL way back in 1975, here I am sharing a few interesting lines of the interview with him. Microbioz …
Russia to start Phase III preliminaries of second COVID-19 antibody in November-December: Report Kumar Jeetendra | October 2, 2020 Russia begins Phase III trials of a second possible vaccine against COVID-19, developed by Siberia’s Vector Institute, in November-December, the TASS news agency cited Russian consumer security watchdog Rospotrebnadzor as saying on October 2. Early-stage clinical trials for the vaccine have been completed on Wednesday.
AstraZeneca resumes COVID-19 immunization preliminary in Japan, US still stopped Kumar Jeetendra | October 2, 2020 AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 vaccine declared in Japan, while adding that it was in talks with regulators on data necessary to restart studies in the United States, where they remain halted. Several global trials of the vaccine, AZD1222, were put on hold last month after an unexplained illness …
Panthera Biopartners concludes Series A financing with Gresham House Ventures as major investor Kumar Jeetendra | October 2, 2020 Panthera Biopartners (Panthera) has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients. Panthera Chairman …
Role of Aerogen Nebulization in High Flow Oxygen Therapy Kumar Jeetendra | October 2, 2020 High flow oxygen therapy is a form of respiratory support used in the hospital where oxygen, often in conjunction with compressed air and humidification, is delivered to a patient at rates of flow higher than that delivered traditionally in oxygen therapy. High flow oxygen therapy is intended to Eliminate most of the anatomic dead space …